Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway. Issue 6 (28th July 2022)

• Record Type: Journal Article
• Authors: Zhao, Mirabella; Lirhus, Sandre; Lördal, Mikael; Langholz, Ebbe; Knudsen, Torben; Voutilainen, Markku; Høivik, Marte Lie; Moum, Bjorn; Anisdahl, Karoline; Sæbø, Borghild; Haiko, Paula; Malmgren, Carolina; Coskun, Mehmet; Melberg, Hans Olav; Burisch, Johan
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 56:Issue 6(2022)
• Page Start: 989
• Page End: 1006
• Publication Date: 2022-07-28
• Subjects: biological era -- epidemiology -- hospitalisation -- inflammatory bowel diseases -- surgery; Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.17145
• Languages: English
• ISSNs: 0269-2813

Abstract

Summary: Background: Despite the increasing use of biologics in patients with inflammatory bowel disease (IBD), real‐world data about outcomes in the era of biologics remain inconclusive. Aims: To investigate trends in surgeries, hospitalisations and medication use in patients with IBD in a multinational, population‐based cohort Methods: We included 42, 894 patients with ulcerative colitis (UC) and 24, 864 with Crohn's disease (CD) who were diagnosed between 2010 and 2017 in Denmark, Norway and Sweden. We extracted data about surgeries, hospitalisations and medications from national registries and compared across countries and diagnosis years. Results: Between 2010 and 2017, 2‐year surgery rates were 4‐7% in UC and 10‐15% in CD and were stable over time. Two‐year hospitalisation rates increased in Denmark (UC: 20% to 35%; CD: 27% to 32%) but were stable in Norway and Sweden (fluctuating between 33% and 37% in UC, and 46% and 52% in CD). Two‐year rates of biologic use increased in both UC (7% to 16% in Denmark, 8% to 18% in Norway) and CD (22% to 26% in Denmark; 21% to 35% in Norway). Two‐year rates of immunomodulator use increased in Norway (from 14% to 23% in UC; 37% to 45% in CD) and Sweden (from 41% to 52% in CD), but were stable in Denmark (between 17% and 21% in UC; 39% to 46% in CD). Conclusion: Between 2010 and 2017, surgery rates among Scandinavian patients with IBD remained stable, with no clear changes in hospitalisation rates despite the increasing use of immunomodulators and biologics. Abstract : Therapeutic mamangement of IBD in Denmark, Sweden and Norway.